A61K - Preparations for medical, dental, or toilet purposes

More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)

Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
12/2004
12/23/2004	CA2527869A1 Method for the treatment of malignancies
12/23/2004	CA2527863A1 Cell surface protein associated with human chronic lymphocytic leukemia
12/23/2004	CA2527843A1 Immunotherapeutics for biodefense
12/23/2004	CA2527830A1 Therapeutic vaccine compositions for the treatment of type 1 diabetes
12/23/2004	CA2527822A1 Room temperature storage of organs
12/23/2004	CA2527621A1 Method of inhibiting tumor growth with anti-tissue factor antibodies
12/23/2004	CA2527236A1 Thiotungstate analogues and uses thereof
12/23/2004	CA2526753A1 Sdr proteins from staphylococcus capitis and their use in preventing and treating infections
12/23/2004	CA2525966A1 Novel immunomodulating peptide
12/23/2004	CA2525917A1 Compositions and methods including a recombinant human mab that promotes cns remyelination
12/23/2004	CA2525784A1 Proteoglycan degrading mutants for treatment of cns
12/23/2004	CA2525782A1 Degradation of glycosaminoglycans in extracellular matrix to treat cns injury
12/23/2004	CA2525778A1 T cell epitopes useful in a severe acute respiratory syndrome (sars) virus vaccine and as diagnostic tools and methods for identifying same
12/23/2004	CA2524639A1 Compositions and methods for reducing scar tissue formation
12/23/2004	CA2520148A1 Compositions and methods for treating coronavirus infection and sars
12/22/2004	EP1488786A1 Melt-extruded orally administrable opioid formulations
12/22/2004	EP1487491A2 Novel of cytokine inhibitors
12/22/2004	EP1487483A2 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
12/22/2004	EP1487423A1 Novel formulation
12/22/2004	EP1169014B1 Antiperspirant compositions
12/22/2004	EP1115373B1 Oral composition with an improved teeth whitening effect
12/22/2004	CN1556856A Vaccines from infectious agents
12/22/2004	CN1556805A Piperidine derivative as NMDA receptor antagonist
12/21/2004	US6833133 Escape mutants of Newcastle disease virus as marker vaccines
12/21/2004	CA2317604C Matrix metalloprotease inhibitors
12/16/2004	WO2004108884A2 Composite materials and particles
12/16/2004	WO2004108728A1 Cannabinoid receptor ligands and uses thereof
12/16/2004	WO2004108094A2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases
12/16/2004	WO2004108093A2 Antiseptic compositions, methods and systems
12/16/2004	WO2004108092A2 Tannate compositions and methods of use
12/16/2004	WO2004108091A2 Antimicrobial flush solutions
12/16/2004	WO2004108090A2 Process for manufacturing oxycodone
12/16/2004	WO2004108089A2 A micro granulate formulation for oral administration in aqueous suspension
12/16/2004	WO2004108088A2 Methods and compositions for interferon therapy
12/16/2004	WO2004108087A2 Gene delivery to organs
12/16/2004	WO2004108086A2 HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-α CONVERTING ENZYME (TACE)
12/16/2004	WO2004108085A2 Methods for the protection of memory and cognition
12/16/2004	WO2004108084A2 Polymorphic forms of naltrexone
12/16/2004	WO2004108083A2 Methods for the selective treatment of tumors by calcium-mediated induction of apoptosis
12/16/2004	WO2004108081A2 Oligonucleotide synthesis with alternative solvents
12/16/2004	WO2004108080A2 Method for treating diseases using hsp90-inhibiting agents in combination with immunosuppressants
12/16/2004	WO2004108079A2 Parkin-interacting proteins
12/16/2004	WO2004108076A2 Anti-hiv benzamide compounds
12/16/2004	WO2004108075A2 Self-warming or self-heating cosmetic and dermatological compositions and method of use
12/16/2004	WO2004108072A2 Delivery of immune response modifier compounds using metal-containing particulate support materials
12/16/2004	WO2004108071A2 Targeting polypeptides to the central nervous system
12/16/2004	WO2004108070A2 Releasable polymeric conjugates based on aliphatic biodegradable linkers
12/16/2004	WO2004108069A2 Compositions and methods for promoting neuronal outgrowth
12/16/2004	WO2004108068A2 4-[4-(4-morpholino)anilino]pyrimidine derivatives, method for preparing thereof and antiviral pharmaceutical composition comprising the same
12/16/2004	WO2004108067A2 Programmed drug delivery system
12/16/2004	WO2004108066A2 Neuronal regeneration and compound administration methods
12/16/2004	WO2004108065A2 Heparanase activity neutralizing anti- heparanase monoclonal antibody and other anti-heparanase antibodies
12/16/2004	WO2004108061A2 Stable injectable pharmaceutical composition of thiopental; method for stabilizing aqueous solutions of thiopental and, use of thiopental for producing a medicament
12/16/2004	WO2004093780A3 Process for the preparation of gabapentin form-ii
12/16/2004	WO2004093779A3 Process for the preparation of gabapentin form-ii
12/16/2004	WO2004091541A3 Methods for the controlled delivery of pharmacologically active compounds
12/16/2004	WO2004089311A3 Polymeric drug agents for the treatment of fibrotic disorders
12/16/2004	WO2004087043A3 Stable ophthalmic formulation containing an antibiotic and a corticosteroid
12/16/2004	WO2004082594A3 Alginate sponge and preparation method thereof
12/16/2004	WO2004082592A3 Metal amino acid chelates having nutritionally relevant anion radical (s)
12/16/2004	WO2004082590A3 A low dose corticosteroid composition
12/16/2004	WO2004080411A3 Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
12/16/2004	WO2004078136A3 Pyridinium salts, compounds and methods of use
12/16/2004	WO2004073647A3 Ultrasonically enhanced saline treatment for burn damaged skin
12/16/2004	WO2004069145A3 Anticancer compounds, process for their preparation and pharmaceutical compositions containing them
12/16/2004	WO2004066929A3 Cycloalkyl containing anilide ligands for the thyroid receptor
12/16/2004	WO2004064735A3 Treatment of benign prostatic hyperplasia
12/16/2004	WO2004062602A3 Compositions and methods for targeted biological delivery of molecular carriers
12/16/2004	WO2004052299A3 Modification of cyclooxygenase and lipoxygenase activity with asteridae extracts and optionally boswellic acid
12/16/2004	WO2004052297A3 TREATMENT OF HSV-RELATED PATHOLOGIES USING ssDNA
12/16/2004	WO2004047737A3 Nucleotide based medicament and method of use for treatment of conditions in humans
12/16/2004	WO2003092582B1 Chimeric ebola virus envelopes and uses therefor
12/16/2004	WO2003063797A8 Cycloalkyl inhibitors of potassium channel function
12/16/2004	US20040254597 Methods and devices for creating electrical block at specific targeted sites in cardiac tissue
12/16/2004	US20040254376 Cyclic amidine derivative
12/16/2004	US20040254246 Treating or preventing hot flashes using prodrugs of GABA analogs
12/16/2004	US20040254231 Antiinflammatory agents; alcoholism; antiallergens; chronic obstructive pulmonary disease; cardiovascular disorders; antiarthritic agents; autoimmune disease; chronic fatigue syndrome; multiple sclerosis
12/16/2004	US20040254220 Histone deacetylase inhibitors
12/16/2004	US20040254170 Administering serotonine receptor antagonist; irritable bowel disorders
12/16/2004	US20040254169 Method of treating functional bowel disorders
12/16/2004	US20040254168 Irritable bowel disorders; serotonine receptor antagonist
12/16/2004	US20040254167 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
12/16/2004	US20040254152 Cognition activators; therapy for brain inflammation; activation of monocytes; reduce brain inflamamtion; Alzheimer's disease; Parkinson's disease; multiple sclerosis; antidepressants; bipolar disorders; Cushing disorders
12/16/2004	US20040254120 Stimulating high density lipoproteins; osteoporosis; detoxification
12/16/2004	US20040254087 Core of active material with wax coating
12/16/2004	US20040253648 Method for creating nuclear receptor activity modulating pharmaceuticals
12/16/2004	US20040253275 Pharmaceutical and cosmetic carrier or composition for topical application
12/16/2004	US20040253270 Nucleic acid encoding infectious, nonpathogenic porcine circovirus type-1(PCV1), which contains immunogenic open reading frame gene of pathogenic PCV2 in place of an ORF gene of PCV1 nucleic acid molecule; means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome
12/16/2004	US20040253249 Pulsatile transdermally administered antigens and adjuvants
12/16/2004	US20040253244 Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions containing the same
12/16/2004	US20040253241 Inducible ligand for alpha1beta1 integrin and uses
12/16/2004	US20040253235 administering interferon-beta (IFN- beta) receptor agonist and tumor associated antigen to increase an immune response against the tumor cells
12/16/2004	US20040253215 Methods and compositions for treating disorders
12/16/2004	US20040253211 analyzing the expression of claudin-3, claudin-4 and claudin-9; if these genes are under-expressed, the transformed/cancerous cell is a metastatic cell; nucleic acid is transfected into the cancerous cell
12/16/2004	US20040253198 Self-warming or self-heating cosmetic and dermatological compositions and method of use
12/16/2004	US20040253183 Apparatus, system and method for generating bubbles on demand
12/16/2004	US20040251418 Filtered backprojection algorithms for compton cameras in nuclear medicine
12/16/2004	CA2550929A1 Antiseptic compositions, methods and systems
12/16/2004	CA2540692A1 Oligonucleotide synthesis with alternative solvents
12/16/2004	CA2528522A1 Antimicrobial flush solutions

1 ... 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 ... 295